[Antibiotic pharmacokinetics in patients with mucoviscidosis].
In this review we summarize the available literature on the pharmacokinetics of antibacterials in cystic fibrosis. A special impact is given on the results of our group which will be put in perspective with the results of other authors. The homogeneity of our patient population allows a valid comparison between patient and volunteer data. We do not confirm the previously suggested strongly enhanced elimination of antibacterials in CF. Our findings have recently been confirmed by other investigators. However, since in the clinical situation a more heterogeneous group of patients is treated it seems rational to increase the dose of the antibacterials by about 20-30%.
Gottschalk
B
B
Klinik und Poliklinik für Kinder- und Jugendmedizin, Universität Essen.
Sörgel
F
F
Wiesemann
H G
HG
Stephan
U
U
Rey
M
M
Böwing
H B
HB
Stehr
C
C
Dominick
H C
HC
Kiosz
D
D
Geldmacher-von Mallinckrodt
M
M
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D002648:Child; D003550:Cystic Fibrosis / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007408:Intestinal Absorption; D008657:Metabolic Clearance Rate; D011552:Pseudomonas Infections / Q000097:blood
D000900:Anti-Bacterial Agents
Antibiotika-Pharmakokinetik bei Patienten mit Mukoviszidose.